Retrospective analysis of biapenem treatment for bacterial infection in very elderly patients

doi:10.5246/jcps.2023.02.013

Abstract

Abstract:

In the present study, we aimed to evaluate the efficacy and safety of biapenem in very elderly (≥ 85 years) patients. A retrospective study was conducted on very elderly patients who received biapenem for at least 72 h and had a complete medical record from January 2016 to December 2017. Baseline characteristics and laboratory test results were recorded and assessed. Finally, 275 unique patients with an average age of 88.5 ± 3.1 years were enrolled. Of these patients, 186 (67.6%) had successful treatment. Univariate analysis of various parameters showed that fever and BUN (serum urea nitrogen) elevation were associated with treatment failure. In contrast, other parameters showed no significant differences between the treatment success group and treatment failure group, which included primary underlying disease, monotherapy, prior use of antibiotics, alanine aminotransferase (ALT), aspartate aminotransferase (AST). Multivariate logistic regression analysis found that fever and BUN elevation were independent risk factors for treatment outcomes. BUN was elevated from 8.8 ± 5.6 to 9.9 ± 5.4 mmol/L after treatment (P = 0.007). Adverse drug reactions were observed in 10.9% (30/275) of patients, and all of these were mild or intermediate. The study suggested that biapenem was efficacious and safe in very elderly patients (≥ 85 years).

Key words: Biapenem, Bacterial infection, Very elderly, Clinical efficacy, Clinical safety

Supporting:

Yuanchao Zhu, Chen Chen, Xin Hu. Retrospective analysis of biapenem treatment for bacterial infection in very elderly patients[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(2): 145-152.

Figures/Tables 5

Table 1. Clinical characteristics of 275 patients treated with biapenem. Univariate analysis of factors associated with clinical outcomes.

Table 2. Body weight-related clinical characteristics. Univariate analysis of factors associated with clinical outcome.

Table 3. Multivariable logistic regression analysis of factors associated with biapenem treatment failure.

Table 4. Effect of biapenem on liver and kidney function (n = 275).

Table 5. Microbiological data of patients. Univariate analysis of factors associated with clinical outcome, n (%).

References 15

[1]	Perry, C.M.; Ibbotson, T. Biapenem. Drugs. 2002, 62, 2221–2234; discussion 2235.
[2]	Malanoski, G.J.; Collins, L.; Wennersten, C.; Moellering, R.C. Jr, Eliopoulos, G.M. In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 1993, 37, 2009–2016.
[3]	Hikida, M.; Kawashima, K.; Yoshida, M.; Mitsuhashi, S. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J. Antimicrob. Chemother. 1992, 30, 129–134.
[4]	Hori, S.; Kanemitsu, K.; Shimada, J. Relation between convulsant activity of biapenem, a new carbapenem, and its binding affinity to GABA receptor. Chemotherapy. 1994, 42, 115–120.
[5]	Writing Group of Guidance for Clinical Trials of Anti-bacterial Drugs. Guidance for Clinical Trials of Anti-bacterial Drugs. Chin. J. Clin. Pharmacol. 2014, 30, 844–856.
[6]	National Health and Family Planning Commission of the People’s Republicof China, State Administration of Traditional Chinese Medicine of the People’s Republic of China, Medical Department Of the People’s Liberation Army General Logistics Department. Guideline principles for clinical use of antibiotics. (version 2015)[S] Beijing, 2015.
[7]	Kozawa, O.; Uematsu, T.; Matsuno, H.; Niwa, M.; Takiguchi, Y.; Matsumoto, S.; Minamoto, M.; Niida, Y.; Yokokawa, M.; Nagashima, S.; Kanamaru, M. Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects. Antimicrob. Agents Chemother. 1998, 42, 1433–1436.
[8]	Zhu, X.; Sun, Y.X.; He, X.J.; Qiu, F.; Li, L.; Zhao, L.M. HPLC-UV method with solid-phase extraction for the quantitative determination of biapenem in human plasma and its application in pharmacokinetic study. J. Chin. Pharm. Sci. 2011, 20, 70–76.
[9]	Burton, D.G.A.; Allen, M.C.; Bird, J.L.E.; Faragher, R.G.A. Bridging the gap: ageing, pharmacokinetics and pharmacodynamics. J. Pharm. Pharmacol. 2005, 57, 671–679.
[10]	Wang, X.H.; Zhang, X.K.; Zong, Z.Y.; Yu, R.J.; Lv, X.J.; Xin, J.B.; Tong, C.H.; Hao, Q.L.; Qin, Z.Q.; Xiong, Y.; Liu, H.; Ding, G.H.; Hu, C.P.; Group, B.S.C. Biapenem versus meropenem in the treatment of bacterial infections: a multicenter, randomized, controlled clinical trial. Indian J. Med. Res. 2013, 138, 995–1002.
[11]	Jia, B.; Lu, P.; Huang, W.X.; Li, C.Z.; Huang, A.L.; Zhou, X.D.; Zhang, W.L.; Wu, G.M.; Zhang, G.F. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections. Chemotherapy. 2010, 56, 285–290.
[12]	Dong, J.; Chen, Y.C.; Xiong, W.; Zhao, Y.F.; Sun, Y.B.; Lu, Y.; Liu, Y.H.; Li, W.Y.; Chen, X.J. Efficacy and safety of biapenem against lower respiratory tract infections in elderly Chinese patients and optimal dosing regimen based on pharmacokinetic/pharmacodynamic analysis. J. Chemother. 2016, 28, 403–410.
[13]	Zhang, Z.X.; Yong, Y.; Tan, W.C.; Shen, L.; Ng, H.S.; Fong, K.Y. Prognostic factors for mortality due to pneumonia among adults from different age groups in Singapore and mortality predictions based on PSI and CURB-65. Singapore Med. J. 2018, 59, 190–198.
[14]	Beier, K.; Eppanapally, S.; Bazick, H.S.; Chang, D.; Mahadevappa, K.; Gibbons, F.K.; Christopher, K.B. Elevation of blood urea nitrogen is predictive of long-term mortality in critically ill patients independent of "normal" creatinine. Crit. Care Med. 2011, 39, 305–313.
[15]	Uranga, A.; Quintana, J.M.; Aguirre, U.; Artaraz, A.; Diez, R.; Pascual, S.; Ballaz, A.; España, P.P. Predicting 1-year mortality after hospitalization for community-acquired pneumonia. PLoS One. 2018, 13, e0192750.